Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Physical Activity Clinical Trial

— WISER-NET  

Official title:

Women In Steady Exercise Research - Neoadjuvant Exercise Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03280836
• Other study ID #: 5517
• Status: Completed
• Phase: N/A
• Start date: August 3, 2017
• Est. completion date: December 21, 2020

Study information

• Verified date: December 2023
• Source: Milton S. Hershey Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators seek to conduct a home based exercise intervention in breast cancer patients whom elect to undergo neoadjuvant chemotherapy. The primary aim of the study is to determine whether breast cancer patients can be enrolled, randomized, retained, and comply with exercise program; and, the feasibility of acquiring, managing and analyzing clinical data.

Description:

Several national and international agencies recommend exercise participation for all persons following a cancer diagnosis. The current evidence suggests that aerobic exercise training is safe during primary adjuvant therapy and improves cardiopulmonary function and patient related outcomes. Cardiopulmonary fitness is highly predictive of overall and cardiovascular specific mortality in women. Specifically, an increase in cardiopulmonary fitness of approximately 10% has been associated with a 19% reduction in risk for CV mortality. This is important as breast cancer patients already present at diagnosis with 31% lower cardiopulmonary fitness levels compared to healthy age-matched women. This enhanced risk for cardiovascular mortality in breast cancer patients is further compounded by cardiotoxic chemotherapy, which causes permanent cardiac damage. Few studies have tested the efficacy of exercise prescriptions that incorporate high intensity aerobic exercise training in cancer patients, especially those receiving chemotherapy. Therefore, the investigators seek to conduct an at home aerobic exercise training intervention in breast cancer patients whom elect to undergo neoadjuvant chemotherapy

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: December 21, 2020
• Est. primary completion date: December 21, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 21 Years and older

Eligibility

3.1 Inclusion Criteria

• Women with a breast cancer diagnosis (Stage I-IIIC)

• Sedentary (< 75 min/wk of moderate intensity exercise over the past month)

• No previous history of anthracycline based chemotherapy

• Absence of heart disease (clinical diagnosis of coronary artery disease, arrhythmias, congenital heart defects, dilated cardiomyopathy, or valvular heart disease)

• Absence of contraindications for neoadjuvant chemotherapy

• Scheduled to receive neoadjuvant chemotherapy

• Primary attending oncologist approval

3.2 Exclusion Criteria

• Absolute contraindications for exercise stress testing

• acute myocardial infarction (3-5 days)

• unstable angina

• uncontrolled arrhythmias causing symptoms or hemodynamic compromise

• syncope

• acute endocarditis

• acute myocarditis or pericarditis

• uncontrolled heart failure

• acute pulmonary embolus or pulmonary infarction

• thrombosis of lower extremities

• suspected dissecting aneurysm

• uncontrolled asthma

• pulmonary edema

• room air desaturation at rest =85%

• respiratory failure

• acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise

• mental impairment leading to inability to cooperate

• decisional impairment

• Non-English speaking

• Women only diagnosed with ductal carcinoma in situ

• Women diagnosed with stage 4 metastatic breast cancer

• Pregnant women

• Men

• Children

Related Conditions & MeSH terms

• Breast Neoplasm
• Breast Neoplasms
• Physical Activity

Intervention

Behavioral:
• Exercise
All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity. The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max.

Locations

Country	Name	City	State
United States	Penn State Hershey Medical Center	Hershey	Pennsylvania
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Milton S. Hershey Medical Center	NRG Oncology

Country where clinical trial is conducted

United States, 

References & Publications (1)

Sturgeon KM, Smith AM, Federici EH, Kodali N, Kessler R, Wyluda E, Cream LV, Ky B, Schmitz KH. Feasibility of a tailored home-based exercise intervention during neoadjuvant chemotherapy in breast cancer patients. BMC Sports Sci Med Rehabil. 2022 Feb 25;14 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acceptability: Percent of Eligible Patients That Provide Consent and Are Enrolled in the Study.	Acceptability of the study will be assessed by documenting the percent of eligible patients that provide consent and are enrolled in the study.	4 weeks
Primary	Participant Adherence to the Exercise Intervention	Tolerability was defined for each intervention exercise training phase by the percent of weekly exercise minutes completed at the prescribed exercise intensity according to the patient's heart rate monitor.	Introduction phase of prescribed exercise training (weeks 1-4), intermediate phase of prescribed exercise training (weeks 5-11), maintenance phase of prescribed exercise training (weeks 12-chemotherapy completion)
Primary	Change in Cardiopulmonary Fitness Level From Baseline to the Window Following Chemotherapy Completion and Before Surgical Resection	Expired gas analysis (oxygen used by the body) during a submaximal treadmill exercise test determined cardiopulmonary fitness. Change between baseline and the window following chemotherapy completion and before surgical resection, was calculated as the value at the test conducted in the window following chemotherapy completion and before surgical resection minus the value at the test conducted at baseline.	Baseline and the window following chemotherapy completion and before surgical resection (no longer than 26 weeks from baseline)